Wednesday, January 28, 2015

Metrics about MOLDX Code Coverage - A Snapshot for January 28, 2015

Recently, I was asked to do an analysis of MolDX coverage by CPT code, and I pulled some of its current data into Excel spreadsheets, available (here; look for small 'down arrow' to download).

Note that MolDX coverage may change at any time, so the cloud spreadsheet just provided represents one day's snapshot of MolDX current coverage and non-coverage webpages.

Details after the break.

MolDX has a webpage of "Approved Genetic Tests."  These are tests that are generally well accepted, and coverage for these tests is just reflected by their serial listingby CPT code.   For example, 81235 (EGFR, common variants) is covered here.   (Webpage).  123 genes are listed by name and code as covered.   This includes 63 germline genetic codes below 81400, where the Tier 2 codes start.  In the Tier 2 series, 81400-81409, 60 genes are listed as covered.

In addition to its webpage for "Approved for Genetic Tests" (which tracks to AMA CPT codes), MolDX also has a web page for "Covered Tests" (document M00023).  There are currently 25 listed articles such as "Oncotype DX Colon Coding and Billing" and "Chimerism Testing Coding Guidelines."  (Webpage).

Finally, there is the grim "Excluded Tests" page (here).   Technically, these tests being "noncovered, without an LCD" are supposed to be excluded for statutory reasons such as being "screening tests" or "preventive care" not currently covered.  However, some seem to be excluded because there is "not enough evidence" which seems more like a reasonable & necessary exclusion.

In any case, the "Excluded Test" spreadsheet lists 899 excluded tests by name.  

  • 48 are Category I/Tier I AMA CPT genetic tests.  
  • 602 of the excluded tests are genes that appear by name in the CPT Tier 2 series.   
  • 21 molecular procedures in the new CY2015 CPT series such as "exome test" and "hearing loss gene panel" are excluded. 
  • Consistent with the MolDX program's fairly liberal use of the unlisted code, 211 noncovered genes are listed by name next to the unlisted code 81479. 
  • Finally, 17 tests in the MAAA Category I or MAAA Administrative Code series are listed as noncovered.
Representing a sampling of the 899 excluded tests, there are links to 53 web articles explaining the reasons for exclusion of some of the tests.  Some of the exclusions seem to be circumstance-based; for example, the BRCA1, BRCA2 genes are absent from the MolDX Covered Test list, and these codes are placed on the MolDX Excluded Test list.   Footing to this, a MolDX article (M00107) states that "carrier testing for risk of disease without signs and symptoms is not a Medicare benefit." On the other hand, the Noridian MAC covers BRCA testing in Medicare patients with a personal history of breast cancer.  Noridian lists the BRCA genes on its "covered" rather than its "noncovered" list (here).

Moving to actual LCDs, MolDX has a webpage listing 13 draft or final LCDs, here.  In a particularly interesting LCD, in January 2015, MolDX proposed to cover (within patient clinical registries) NGS test panels in some patients with advanced lung cancer, see here.


On February 12, 2015, MolDX posting Version 7 of its updated pricing for the limited number of covered Tier 2 genes.   Pricing within a Tier 2 category can vary substantially.   For example, within Tier 2 (81401), pricing ranges from $54 for PAX8 to $204 for EWSR1, a four-fold difference.  Within Tier 5 (81404), pricing varies from $95 for RET to $640 for VHL, more than a six-fold difference.   Link here; chart below: